Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Recent Advances in Pulmonary Hypertension
Author(s): Akshyaya Pradhan , Richa Tyagi , Prachi Sharma , et al Added: 1 year ago

Prevention & Chronic Conditions
Research Area(s) / Expertise:
Unusual Presentations of Thyrotoxic Valvulopathy in Adult Thyrotoxicosis
Author(s): Andro Pramana Witarto , Bendix Samarta Witarto , Shidi Laras Pramudito , et al Added: 1 year ago

Imaging & Diagnostics

Prevention & Chronic Conditions
Staging of Heart Failure with Preserved Ejection Fraction
Author(s): Anastasia Shchendrygina , Ilya Giverts , Mariya Tokmakova , et al Added: 1 year ago

Imaging & Diagnostics

Heart Failure
Vineet Agrawal
Job title: Assistant Professor of Medicine
Personal History Dr Vineet Agrawal is a physician-scientist and is Assistant Professor of Medicine at the Vanderbilt University Medical Center. He is from Omaha, Nebraska.1, 2, 5 Academic History In 2006, Dr Agrawal completed his undergraduate training at Duke University in Biomedical and Electrical Engineering. In 2012, he completed his MD and PhD in the Medical Scientist Training… View more
Research Area(s) / Expertise: Job title: Director of the National Pulmonary Hypertension Service
Job title: Associate Professor
Research Area(s) / Expertise:
Research Area(s) / Expertise: Job title: Assistant Professor of Medicine and Director of the Pulmonary Hypertension Clinic
ACC 25 Late-Breaking Discussion: The ADVANCE-HTN Trial
Author(s): Harriette Van Spall , Luke Laffin Added: 1 year ago
ACC 25 - ADVANCE-HTN shows lorundrostat, an aldosterone synthase inhibitor, effectively lowered 24-hour blood pressure in patients with uncontrolled and true resistant hypertension.Late-breaker discussion host, Dr Harriette Van Spall (McMaster University, Hamilton, CA) is joined by Dr Luke Laffin (Cleveland Clinic, Cleveland, OH, US) to discuss the key findings from the ADVANCE-HTN trial… View more

Prevention & Chronic Conditions